Tuberculosis Trial Launched

The TB Alliance will test a new combination of drugs to combat normal and multi-drug-resistant tuberculosis.

Written byHannah Waters
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA COMMONS, DVORTYGIRL

The TB Alliance is continuing its charge to develop a new drug regimen for people with tuberculosis, jumping regulatory hurdles to test several new combinations of drugs. Yesterday, the non-profit organization announced that they would begin a second clinical trial to test a new drug combination that can be taken for less time and, hopefully, work more effectively against the disease.

Currently, tuberculosis patients are prescribed a handful of antibiotics to be taken every day for 6 months. And if they develop a multi-drug-resistant form of tuberculosis, they will receive daily injections for 6 months, followed by 18 months of pill-popping.

In September 2010, the TB Alliance launched the first new phase II trial for new tuberculosis medicines in 50 years, testing a three-drug regimen: ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
December digest cover image of a wooden sculpture comprised of multiple wooden neurons that form a seahorse.
December 2025, Issue 1

Wooden Neurons: An Artistic Vision of the Brain

A neurobiologist, who loves the morphology of cells, turns these shapes into works of art made from wood.

View this Issue
Stacks of cell culture dishes, plates, and flasks with pink cell culture medium on a white background.

Driving Innovation with Cell Culture Essentials

Merck
Stacks of cell culture dishes, plates, and flasks with pink cell culture medium on a white background.

Driving Innovation with Cell Culture Essentials

MilliporeSigma purple logo
Abstract wireframe sphere with colorful dots and connecting lines representing the complex cellular and molecular interactions within the tumor microenvironment.

Exploring the Inflammatory Tumor Microenvironment 

Cellecta logo
An image of a DNA sequencing spectrum with a radial blur filter applied.

A Comprehensive Guide to Next-Generation Sequencing

Integra Logo

Products

brandtech logo

BRANDTECH® Scientific Announces Strategic Partnership with Copia Scientific to Strengthen Sales and Service of the BRAND® Liquid Handling Station (LHS) 

Top Innovations 2026 Contest Image

Enter Our 2026 Top Innovations Contest

Biotium Logo

Biotium Expands Tyramide Signal Amplification Portfolio with Brighter and More Stable Dyes for Enhanced Spatial Imaging

Labvantage Logo

LabVantage Solutions Awarded $22.3 Million U.S Customs and Border Protection Contract to Deliver Next-Generation Forensic LIMS